Friday, September 4, 2026

Provident Bancorp, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

January 14, 2021

Provident Bancorp, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Molina Healthcare Inc

24.7% sales growth and 40.03% return on equity

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces.

Molina Healthcare Inc's sales growth this year is expected to be 16% and 17.3% for next year.

Year-on-year quarterly revenue growth grew by 16%, now sitting on 17.66B for the twelve trailing months.

Molina Healthcare Inc's sales growth for the next quarter is 24.7%. The company's growth estimates for the present quarter and the next is a negative 46.9% and 21.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 40.03%.

Volatility

Molina Healthcare Inc's last day, last week, and last month's average volatility was 0.43%, 2.76%, and 0.60%, respectively.

Molina Healthcare Inc's last day, last week, and last month's high and low average amplitude percentage was 3.35%, 4.40%, and 3.03%, respectively.

Molina Healthcare Inc's Stock Yearly Top and Bottom Value

Molina Healthcare Inc's stock is valued at $243.10 at 19:22 EST, under its 52-week high of $246.72 and way higher than its 52-week low of $102.85.

Molina Healthcare Inc's Moving Average

Molina Healthcare Inc's worth is way higher than its 50-day moving average of $210.05 and way above its 200-day moving average of $194.64.

2. Alexion Pharmaceuticals, Inc.

9.5% sales growth and 8.92% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals, Inc.'s sales growth this year is expected to be 20.8% and 9.2% for next year.

Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 5.86B for the twelve trailing months.

Alexion Pharmaceuticals, Inc.'s sales growth for the next quarter is 9.5%. The company's growth estimates for the present quarter and the next is a negative 5.5% and negative -3.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.92%.

Volatility

Alexion Pharmaceuticals, Inc.'s last day, last week, and last month's average volatility was 1.03%, 0.14%, and 1.49%, respectively.

Alexion Pharmaceuticals, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 0.85%, 1.22%, and 1.47%, respectively.

Alexion Pharmaceuticals, Inc.'s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals, Inc.'s stock is valued at $157.35 at 19:22 EST, below its 52-week high of $160.03 and way higher than its 52-week low of $72.67.

Alexion Pharmaceuticals, Inc.'s Moving Average

Alexion Pharmaceuticals, Inc.'s value is way above its 50-day moving average of $140.79 and way above its 200-day moving average of $119.39.

3. Provident Bancorp, Inc.

14.8% sales growth and 5.45% return on equity

Provident Bancorp, Inc. operates as a holding company for The Provident Bank that provides various financial services to individuals and small businesses in the United States.

Provident Bancorp, Inc.'s sales growth this year is anticipated to be 23% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 25.6%, now sitting on 47.86M for the twelve trailing months.

Provident Bancorp, Inc.'s sales growth for the next quarter is 14.8%. The company's growth estimates for the ongoing quarter and the next is 57.1% and 57.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.45%.

Volatility

Provident Bancorp, Inc.'s last day, last week, and last month's average volatility was a negative 1.75%, a negative 0.42%, and a positive 0.49%, respectively.

Provident Bancorp, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.77%, 2.85%, and 3.93%, respectively.

Provident Bancorp, Inc.'s Stock Yearly Top and Bottom Value

Provident Bancorp, Inc.'s stock is valued at $11.97 at 19:22 EST, below its 52-week high of $12.55 and way above its 52-week low of $7.21.

Provident Bancorp, Inc.'s Moving Average

Provident Bancorp, Inc.'s value is higher than its 50-day moving average of $11.24 and way higher than its 200-day moving average of $8.88.

4. Euroseas Ltd.

7.1% sales growth and 9.93% return on equity

Euroseas Ltd.

Euroseas Ltd.'s sales growth this year is expected to be 31.6% and 17.2% for next year.

Year-on-year quarterly revenue growth grew by 19.7%, now sitting on 54.58M for the twelve trailing months.

Euroseas Ltd.'s sales growth for the next quarter is 7.1%. The company's growth estimates for the present quarter and the next is 127.8% and 56.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.93%.

Volatility

Euroseas Ltd.'s last day, last week, and last month's average volatility was 16.23%, 4.56%, and 0.95%, respectively.

Euroseas Ltd.'s last day, last week, and last month's high and low average amplitude percentage was 16.78%, 9.61%, and 8.87%, respectively.

Euroseas Ltd.'s Stock Yearly Top and Bottom Value

Euroseas Ltd.'s stock is valued at $6.73 at 19:22 EST, under its 52-week high of $6.82 and way higher than its 52-week low of $1.23.

Euroseas Ltd.'s Moving Average

Euroseas Ltd.'s worth is way above its 50-day moving average of $5.01 and way higher than its 200-day moving average of $3.24.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com